MX2022003820A - Metodos de tratamiento para modificar la hermodinamica. - Google Patents

Metodos de tratamiento para modificar la hermodinamica.

Info

Publication number
MX2022003820A
MX2022003820A MX2022003820A MX2022003820A MX2022003820A MX 2022003820 A MX2022003820 A MX 2022003820A MX 2022003820 A MX2022003820 A MX 2022003820A MX 2022003820 A MX2022003820 A MX 2022003820A MX 2022003820 A MX2022003820 A MX 2022003820A
Authority
MX
Mexico
Prior art keywords
treatment
human subject
hemodynamics
modifying
methods
Prior art date
Application number
MX2022003820A
Other languages
English (en)
Inventor
Roelof Peter Pickkers
Gert Wensvoort
Original Assignee
Ebi Anti Sepsis B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ebi Anti Sepsis B V filed Critical Ebi Anti Sepsis B V
Publication of MX2022003820A publication Critical patent/MX2022003820A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona un método de tratamiento que comprende la administración de un péptido AQGV, o un análogo funcional del mismo, a un sujeto humano, donde el sujeto humano opcionalmente tiene una función renal deteriorada, en donde el tratamiento para administrar un péptido AQGV comprende mantener o mejorar la estabilidad hemodinámica en el sujeto humano, como un sujeto humano que padece o se considera que padece la enfermedad de Clarkson (CLS).
MX2022003820A 2019-09-30 2020-09-30 Metodos de tratamiento para modificar la hermodinamica. MX2022003820A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908442P 2019-09-30 2019-09-30
US202063045752P 2020-06-29 2020-06-29
PCT/NL2020/050605 WO2021066649A1 (en) 2019-09-30 2020-09-30 Methods of treatment for modifying hemodynamics

Publications (1)

Publication Number Publication Date
MX2022003820A true MX2022003820A (es) 2022-09-19

Family

ID=72811922

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003820A MX2022003820A (es) 2019-09-30 2020-09-30 Metodos de tratamiento para modificar la hermodinamica.

Country Status (10)

Country Link
US (1) US20220370543A1 (es)
EP (1) EP4037701A1 (es)
JP (1) JP2023503790A (es)
KR (1) KR20220106114A (es)
AU (1) AU2020360113A1 (es)
CA (1) CA3152346A1 (es)
CL (1) CL2022000786A1 (es)
CO (1) CO2022005113A2 (es)
MX (1) MX2022003820A (es)
WO (1) WO2021066649A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022012506A (es) * 2020-04-06 2023-01-16 Biotempt Bv Métodos y medios para modificar la hemodinámica en infecciones.
AU2021354766A1 (en) * 2020-09-30 2023-05-11 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
AU2022359382A1 (en) * 2021-10-05 2024-05-02 Biotempt B.V. Angiogenic control, preferably combined with glycaemic control.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1466612A1 (en) * 2003-04-08 2004-10-13 Biotempt B.V. Treatment of inflammation and sepsis with hCG derived peptides
PT2120991E (pt) * 2007-02-12 2014-05-02 Biotempt Bv Tratamento d a hemorragia traumática com oligopéptidos curtos
WO2009014440A1 (en) * 2007-07-23 2009-01-29 Biotempt B.V. Inhibition of renal ischemia reperfusion injury by synthetic oligopeptides

Also Published As

Publication number Publication date
WO2021066649A1 (en) 2021-04-08
AU2020360113A1 (en) 2022-04-14
EP4037701A1 (en) 2022-08-10
JP2023503790A (ja) 2023-02-01
CA3152346A1 (en) 2021-04-08
KR20220106114A (ko) 2022-07-28
CL2022000786A1 (es) 2022-11-04
US20220370543A1 (en) 2022-11-24
CO2022005113A2 (es) 2022-06-21

Similar Documents

Publication Publication Date Title
MX2022003820A (es) Metodos de tratamiento para modificar la hermodinamica.
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DK1613347T3 (da) Humaniserede antistoffer, der genkender beta-amyloidpeptid
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
TW200636066A (en) Humanized antibodies that recognize beta amyloid peptide
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
EA202192625A1 (ru) Лиганды псевдокиназы tyk2
NO20076241L (no) Terapier for vaskulaere sykdommer
EA201400423A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
ZA202202363B (en) Antibodies against ilt2 and use thereof
NO20055309D0 (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
MX2021015651A (es) Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
MX2019002382A (es) Anticuerpos anti-gremlin-1 (grem1) y metodos de uso de los mismos para tratar la hipertension arterial pulmonar.
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
EA200501620A1 (ru) Лечение состояний, включающих амилоидные бляшки
WO2020086479A9 (en) Dosing
MX2021011183A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria.
MX2021002936A (es) Uso de recambio plasmatico de bajo volumen para el tratamiento de la enfermedad de alzheimer en etapas temprana y moderada.
MX2020009305A (es) Uso de un anticuerpo anti-p-selectina.
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
MX2023001055A (es) Inmunógenos derivados de la proteína de la espícula del sars-cov2.
MX2020008262A (es) Tratamiento del síntoma más molesto (smm) asociado a la migraña usando anticuerpos anti-cgrp.